Study of Selenoprotein P as a Marker of Hepatocellular Carcinoma Diagnosis and Therapeutic Intervention Outcome

• Published in: International journal of tropical disease & health 2022-05, p.19-26
• Main Authors: Elqatary, Yara Mohamed, Shehata, Mona Ahmed Helmy, Elenein, Amany Mohamed Abo, Ali, Lobna Ahmed Fahmy Abo
• Format: Article
• Language: English
• ISSN: 2278-1005; 2278-1005
• DOI: 10.9734/ijtdh/2022/v43i1030618

Background: Hepatocellular carcinoma is the main public health issue on a global scale, and its diagnosis remains difficult. HCC is now believed to be a common malignancy and a foremost cause of death in Egypt, owing to the high prevalence of cirrhosis associated with chronic HCV. Its incidence has increased in recent years, and it is expected that there will be continuous a rise in the number of occurrences. This study aimed to evaluate the role of serum selenoprotein P as a marker for diagnosis and follow up of therapeutic intervention outcome in hepatocellular carcinoma patients. Methods: This was a prospective study that took place in Tropical medicine department, Tanta university. Seventy patients with cirrhosis of the liver were included, either with or without hepatocellular carcinoma. The studied patients were divided into group I A of 20 HCC patients who underwent HCC therapeutic intervention, those patients were evaluated before and after their therapeutic intervention, group I B of 25 HCC patients who did not undergo HCC therapeutic intervention as unsuitable and group II of 25 patients with liver cirrhosis as controls Results: Selenoprotein P was decreased significantly in group IB than group IA and group II (P